These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19761871)

  • 41. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way?
    Alisi A; Nobili V
    Nat Rev Gastroenterol Hepatol; 2011 Jul; 8(8):425-6. PubMed ID: 21750513
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study.
    Geier A; Eichinger M; Stirnimann G; Semela D; Tay F; Seifert B; Tschopp O; Bantel H; Jahn D; Marques Maggio E; Saleh L; Bischoff-Ferrari HA; Müllhaupt B; Dufour JF
    Scand J Gastroenterol; 2018 Sep; 53(9):1114-1120. PubMed ID: 30270688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study.
    Hong ES; Kim EK; Kang SM; Khang AR; Choi SH; Park KS; Jang HC; Lim S
    J Gastroenterol Hepatol; 2014; 29(7):1449-57. PubMed ID: 24611967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.
    Brunt EM; Kleiner DE; Wilson LA; Unalp A; Behling CE; Lavine JE; Neuschwander-Tetri BA;
    Hepatology; 2009 Mar; 49(3):809-20. PubMed ID: 19142989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.
    Lavine JE
    J Pediatr; 2000 Jun; 136(6):734-8. PubMed ID: 10839868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.
    Krakoff J; Clark JM; Crandall JP; Wilson C; Molitch ME; Brancati FL; Edelstein SL; Knowler WC;
    Obesity (Silver Spring); 2010 Sep; 18(9):1762-7. PubMed ID: 20186137
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
    Westfall E; Jeske R; Bader AR
    Am Fam Physician; 2020 Nov; 102(10):603-612. PubMed ID: 33179890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions.
    Duseja A; Das A; Dhiman RK; Chawla YK; Thumburu KT; Bhadada S; Bhansali A
    Ann Hepatol; 2007; 6(4):222-6. PubMed ID: 18007551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease.
    Nobili V; Manco M; Devito R; Ciampalini P; Piemonte F; Marcellini M
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1553-61. PubMed ID: 17206944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.
    Corey KE; Vuppalanchi R; Vos M; Kohli R; Molleston JP; Wilson L; Unalp-Arida A; Cummings OW; Lavine JE; Chalasani N;
    J Pediatr Gastroenterol Nutr; 2015 Mar; 60(3):360-7. PubMed ID: 25714579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonalcoholic fatty liver disease in the pediatric population.
    Lavine JE; Schwimmer JB
    Clin Liver Dis; 2004 Aug; 8(3):549-58, viii-ix. PubMed ID: 15331063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medical therapy for nonalcoholic fatty liver disease in children and adolescents.
    Andrews DB; Lavine JE
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):1-3. PubMed ID: 22149573
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
    Ratziu V; Charlotte F; Bernhardt C; Giral P; Halbron M; Lenaour G; Hartmann-Heurtier A; Bruckert E; Poynard T;
    Hepatology; 2010 Feb; 51(2):445-53. PubMed ID: 19877169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.
    Patton HM; Yates K; Unalp-Arida A; Behling CA; Huang TT; Rosenthal P; Sanyal AJ; Schwimmer JB; Lavine JE
    Am J Gastroenterol; 2010 Sep; 105(9):2093-102. PubMed ID: 20372110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.
    Wang CH; Leung CH; Liu SC; Chung CH
    J Formos Med Assoc; 2006 Sep; 105(9):743-52. PubMed ID: 16959622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metformin in nonalcoholic steatohepatitis: a randomized controlled trial.
    Kazemi R; Aduli M; Sotoudeh M; Malekzadeh R; Seddighi N; Sepanlou SG; Merat S
    Middle East J Dig Dis; 2012 Jan; 4(1):16-22. PubMed ID: 24829630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
    Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.